These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32900459)

  • 21. Letter by Behrouz et Al regarding article, "Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion".
    Behrouz R; Mutgi SA; Silver B
    Stroke; 2015 Jun; 46(6):e149. PubMed ID: 25899241
    [No Abstract]   [Full Text] [Related]  

  • 22. EMS mythology. EMS myth #2. Thombolytic therapy is the standard of care for acute ischemic stroke.
    Bledsoe BE
    Emerg Med Serv; 2003 Apr; 32(4):63-5. PubMed ID: 12705219
    [No Abstract]   [Full Text] [Related]  

  • 23. Emergency physician survey: recombinant tissue plasminogen activator for stroke.
    Walsh M; Fromm G
    Ann Emerg Med; 2006 Mar; 47(3):297. PubMed ID: 16492504
    [No Abstract]   [Full Text] [Related]  

  • 24. Recombinant tissue plasminogen activator: in my community hospital ED, will early administration of rt-PA to patients with the initial diagnosis of acute ischemic stroke reduce mortality and disability?
    Wyer PC; Osborn HH
    Ann Emerg Med; 1997 Nov; 30(5):629-38. PubMed ID: 9360575
    [No Abstract]   [Full Text] [Related]  

  • 25. Tissue plasminogen activator (tPA) for stroke.
    Clin Privil White Pap; 2001 Jul; (65):1-8. PubMed ID: 11718176
    [No Abstract]   [Full Text] [Related]  

  • 26. Emergency physician survey: recombinant tissue plasminogen activator for stroke.
    Mann J
    Ann Emerg Med; 2006 Oct; 48(4):476; author reply 477. PubMed ID: 16997689
    [No Abstract]   [Full Text] [Related]  

  • 27. Response to letter regarding article, “smoking-thrombolysis paradox: recanalization and reperfusion rates after intravenous tissue plasminogen activator in smokers with ischemic stroke”.
    Kufner A; Nolte CH; Ebinger M
    Stroke; 2013 May; 44(5):e59. PubMed ID: 23741741
    [No Abstract]   [Full Text] [Related]  

  • 28. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes.
    Fonarow GC; Smith EE; Saver JL; Reeves MJ; Bhatt DL; Grau-Sepulveda MV; Olson DM; Hernandez AF; Peterson ED; Schwamm LH
    Circulation; 2011 Feb; 123(7):750-8. PubMed ID: 21311083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transition of European Cooperative Acute Stroke Study III results to clinical practice: ninety-day outcomes in a US cohort.
    Cronin CA; Langenberg P; Dutta TM; Kittner SJ
    Stroke; 2013 Dec; 44(12):3544-6. PubMed ID: 24092551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Letter by Plas et al regarding article, "smoking-thrombolysis paradox: recanalization and reperfusion rates after intravenous tissue plasminogen activator in smokers with ischemic stroke".
    Plas GJ; Uyttenboogaart M; Luijckx GJ
    Stroke; 2013 May; 44(5):e58. PubMed ID: 23559266
    [No Abstract]   [Full Text] [Related]  

  • 31. Acute ischemic stroke and timing of treatment--reply.
    Saver JL; Fonarow GC; Schwamm LH
    JAMA; 2013 Nov; 310(17):1856-7. PubMed ID: 24193086
    [No Abstract]   [Full Text] [Related]  

  • 32. Letter by Alves et al Regarding Article, "Effect of Right Insular Involvement on Death and Functional Outcome After Acute Ischemic Stroke in the IST-3 Trial (Third International Stroke Trial)".
    Alves JN; Pinho J; Ferreira C
    Stroke; 2017 Mar; 48(3):e91. PubMed ID: 28174329
    [No Abstract]   [Full Text] [Related]  

  • 33. Agreement with evidence for tissue Plasminogen Activator use among emergency physicians: a cross-sectional survey.
    Grady AM; Bryant J; Carey ML; Paul CL; Sanson-Fisher RW; Levi CR
    BMC Res Notes; 2015 Jun; 8():267. PubMed ID: 26111807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response by Sposato et al to Letter Regarding Article, "Effect of Right Insular Involvement on Death and Functional Outcome After Acute Ischemic Stroke in the IST-3 Trial (Third International Stroke Trial)".
    Sposato LA; Wardlaw JM; Hachinski V
    Stroke; 2017 Mar; 48(3):e92. PubMed ID: 28174325
    [No Abstract]   [Full Text] [Related]  

  • 35. Intravenous Recombinant Tissue Plasminogen Activator and Ischemic Stroke: Focused Update of 2010 Clinical Practice Advisory From the American Academy of Emergency Medicine.
    Meurer WJ; Barth B; Abraham M; Hoffman JR; Vilke GM; DeMers G
    J Emerg Med; 2018 May; 54(5):723-730. PubMed ID: 29545057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of ischemic stroke beyond 3 hours: is time really brain?
    von Kummer R
    Neuroradiology; 2019 Feb; 61(2):115-117. PubMed ID: 30377747
    [No Abstract]   [Full Text] [Related]  

  • 37. Dynamic changes in plasma tissue plasminogen activator, plasminogen activator inhibitor-1 and beta-thromboglobulin content in ischemic stroke.
    Zhuang P; Wo D; Xu ZG; Wei W; Mao HM
    J Clin Neurosci; 2015 Jul; 22(7):1123-7. PubMed ID: 26002716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of tissue plasminogen activator, ischemic stroke, and potential legal issues.
    Liang BA; Lew R; Zivin JA
    Arch Neurol; 2008 Nov; 65(11):1429-33. PubMed ID: 19001160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Letter re: Why are acute ischemic stroke patients not receiving IV tPA? Results from a national registry.
    Hu Z; Chen C; Zeng L
    Neurology; 2017 Apr; 88(14):1383. PubMed ID: 28373370
    [No Abstract]   [Full Text] [Related]  

  • 40. Response by Darcourt and Cognard to Letter Regarding Article, "Predictive Value of Susceptibility Vessel Sign for Arterial Recanalization and Clinical Improvement in Ischemic Stroke".
    Darcourt J; Cognard C
    Stroke; 2019 May; 50(5):e135. PubMed ID: 30917755
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.